OraSure Technologies Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between August 15, 2019, and August 19, 2019. OraSure Technologies, Inc. (OSUR) announced and completed the sale of its cryosurgical systems business to CryoConcepts LP.
Key Financial Metrics and Transaction Details
- Transaction Value: $12.0 million in cash.
- Assets Sold: Professional Histofreezer product line, private label cryosurgical products, related patents, trademarks, customer contracts, and goodwill.
- Closing Date: August 16, 2019.
- Financial Statements: Unaudited pro forma condensed consolidated financial statements reflecting the sale are filed as Exhibit 99.2.
Material Changes and Strategic Shifts
The Company exited the cryosurgical systems market through the disposition of the Business. As part of the agreement, OraSure agreed to non-competition and non-solicitation provisions for three years, prohibiting the Company from conducting or acquiring a greater than 10% voting interest in entities developing competing cryosurgical products for benign skin lesion removal.
Guidance, Outlook, and Management Commentary
On August 19, 2019, the Company issued a press release (Exhibit 99.1) providing updated financial guidance for the third quarter and full-year 2019 to reflect the impact of the asset disposition. The filing notes that the Company will provide transitional services to the buyer. Specific numerical guidance figures are not detailed in the text of this 8-K but are referenced in the attached press release.
Investor Verification Checklist
- Review Exhibit 99.1 for specific updated revenue and earnings guidance for Q3 and full-year 2019.
- Examine Exhibit 99.2 for pro forma financial impacts on the balance sheet and income statement.
- Verify the terms of the transition services agreement and the scope of the three-year non-compete clause in Exhibit 2.1.
- Confirm the treatment of the $12.0 million cash proceeds in the Company's liquidity position.